This is highlighted by loss-of-function NCC mutations underlying hypotensive Gitelman's syndrome or activation of NCC in hypertensive pseudohypoaldosteronism type II (PHAII or Gordon syndrome) (3, 4, 5). This evidence concerns the gene SLC12A3 and pseudohypoaldosteronism type 2.